Researchers built a three-layer human blood-vessel model that shows how fibroblasts amplify the vascular pathology of ...

Researchers have used CRISPR-Cas9 to remove CD28 from donor T cells and prevent fratricide before equipping them with ...

Wave Life Sciences has reached alignment with the US Food and Drug Administration on a registrational pathway for WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin ...

Screening ionisable lipids with a gene-editor-sized RNA identified LC-1, an LNP component that retained potency as cargo ...

Researchers in Germany have identified a SOX9-responsive regulatory route to IRF6, a major orofacial-cleft risk gene, in cranial neural crest cells rather than only in oral epithelium. CRISPR-Cas9 ...

The minimal residual disease-positive cohort opens as part of the pivotal-stage development of Soficabtagene Geleucel (Sofi-cel), an off-the-shelf CAR-T cell therapy under evaluation for relapsed or ...

CMN Intelligence has released the CMN Clinical Trials Q2 2026 Global Report, based on data from the CRISPR Medicine News Global Clinical Trials... A mutation-agnostic CRISPR-Cas strategy that inserts ...

A gene-edited pig kidney kept a patient with end-stage kidney disease dialysis-free for 271 days, then failed and was removed without leaving the recipient sensitised against human donors. Eighty-two ...

Rationally engineered chimeric attachment sites raise the efficiency with which the serine integrase Bxb1 inserts large DNA cassettes into targeted loci in both human cells and rice. Paired with an ...

Phase 1 study in patients with mCRPC expected to begin enrollment in the fourth quarter of 2026 REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology ...

Emerging from stealth, Kindred announces peer-reviewed results in The CRISPR Journal, demonstrating the creation of two healthy beagles with a targeted CRISPR-Cas9 edit that eliminates the major dog ...

A six-year-old girl died after receiving an experimental CRISPR-Cas base-editing treatment for a nonfatal neurodevelopmental disorder in China. The fatal immune reaction followed preclinical safety ...